Pharma BD Deal Intelligence

Glioblastoma Foundation, Inc. / Basilea Pharmaceutica Ltd

2024 · Asset Purchase · Complete

Basilea transferred all rights to its oncology candidate lisavanbulin (BAL101553), which had completed Phase 1/2 studies in glioblastoma, to the non-profit Glioblastoma Foundation as Basilea refocuses on anti-infectives. The Foundation will continue patient access programs and advance clinical development in the US; the initial purchase price was not disclosed, and Basilea retains a fixed double-digit percentage of any future commercial partnership proceeds.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals